source
- Syndax halts development of Niktimvo after Phase 2 failure in IPF trialSyndax announced it is stopping work on its experimental drug Niktimvo for idiopathic pulmonary fibrosis (IPF) after the compound did not meet its primary endpoints in a placebo-controlled Phase 2…
- Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefitMirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage s…